מאמרים בתחום סרטן השד

 

1. Expert Rev Anticancer Ther. 2014 Jun;14(6):705-10. doi:

10.1586/14737140.2014.895667. Epub 2014 Mar 10.

 

Optimal management of sarcomas of the breast: an update.

 

Nizri E(1), Merimsky O, Lahat G.

 

Author information:

(1)The Department of General Surgery, Tel-Aviv Sourasky Medical Center, Tel-Aviv,

Israel.

 

Breast sarcomas are rare mesenchymal-derived breast tumors. The small number of

patients, the different histological subtypes, and the variation in clinical

practice impairs the ability to draw firm practice recommendations. Patient

management is often extrapolated from other soft tissue sarcomas, mostly of the

extremities in which more clinical data is available. Surgical resection with

negative margins is the goal of treatment, irrespective of the surgical

procedure; the implication of radiation and chemotherapy is variable. Further

advances in treatment should follow the assembly of breast sarcoma patients in

specific cancer networks in specialized sarcoma referral centers. The

characterization of molecular pathways active in tumorogenesis of these tumors

may pave the way for the application of novel therapeutic agents.

 

PMID: 24611696  [PubMed - indexed for MEDLINE]

 

 

2. Oncol Lett. 2013 Feb;5(2):424-426. Epub 2012 Dec 5.

 

The evolution in melanoma treatment as a reflection of precision-oriented

medicine.

 

Kushnir I(1), Merimsky O.

 

Author information:

(1)Department of Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv 64239,

Israel.

 

Until recently, metastatic melanoma was a disease with limited treatment options

and a poor prognosis. Dacarbazine was accepted as the standard treatment for

melanoma in the 1970s, and despite inducing an overall survival of approximately

7.4 months, it remained so until relatively recently. In the last few years,

significant advances in the molecular understanding of this disease have

facilitated the development of novel and promising drugs. Precision-oriented

medicine is currently revolutionizing the practice of oncology. Targeted

therapies have demonstrated great potential in treating melanoma and various

other types of cancer, including breast, colorectal and non-small cell lung

cancer. Here, we review the evolution of melanoma treatment from single-agent

chemotherapy to combination therapy, the emergence of immunotherapy in melanoma

and the development of targeted therapies, such as the use of the BRAF inhibitor

as a treatment agent. The ability to treat melanoma according to the fingerprint

of the tumor reflects an overall change in the practice of oncology.

 

PMCID: PMC3573132

PMID: 23420786  [PubMed]

 

 

3. Lancet Oncol. 2013 Jan;14(1):72-80. doi: 10.1016/S1470-2045(12)70525-9. Epub 2012

Dec 12.

 

Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast

cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial.

 

Mackey JR(1), Martin M, Pienkowski T, Rolski J, Guastalla JP, Sami A, Glaspy J,

Juhos E, Wardley A, Fornander T, Hainsworth J, Coleman R, Modiano MR, Vinholes J,

Pinter T, Rodríguez-Lescure A, Colwell B, Whitlock P, Provencher L, Laing K,

Walde D, Price C, Hugh JC, Childs BH, Bassi K, Lindsay MA, Wilson V, Rupin M,

Houé V, Vogel C; TRIO/BCIRG 001 investigators.

 

Collaborators: Martinez JL, Mickiewicz E, Roffo H, Orti R, Schuller J, Teixeira

LC, Allan S, Chang J, Drolet Y, Dufresne J, Gelmon K, Holland D, Lesperance B,

Mackinnon J, Potvin C, Rubin S, Sehdev S, Trudeau M, Verma S, Spadafora S, Yelle

L, Abrahamova J, Finek J, Azim HA, El Zawahry H, Oberhoff C, Georgoulias V, Boer

K, Lurie H, Merimsky O, Steiner M, Karnicka-Mlodkowska H, Chumbo M, Goncalves I,

Koza I, Moodley D, Alba Conejo E, Lopez IA, Torres AA, Aguilar EA, Cassinello J,

Samper FL, Vega JM, Lopez RL, Gandia BM, Rosales AM, Torres A, Nylen U, Sherwin

E, Garbino C, Viola A, Avery B, Beck T, Begas A, George C, Glaspy J, Chap L,

Graham B, Iannotti N, Hainsworth J, Limentani S, Marcom K, O'Rourke M, Robert N,

Schnell F, Theall K, Tongol J, Beeker T, Kerns R, George C, Dobbs T, Campos L.

 

BACKGROUND: We compared standard adjuvant anthracycline chemotherapy with

anthracycline-taxane combination chemotherapy in women with operable

node-positive breast cancer. Here we report the final, 10-year follow-up analysis

of disease-free survival, overall survival, and long-term safety.

METHODS: BCIRG 001 was an open label, phase 3, multicentre trial in which 1491

patients aged 18-70 years with node-positive, early breast cancer and a Karnofsky

score of 80% or more were randomly assigned to adjuvant treatment with docetaxel,

doxorubicin, and cyclophosphamide (TAC) or fluorouracil, doxorubicin, and

cyclophosphamide (FAC) every 3 weeks for six cycles. Randomisation was stratified

according to institution and number of involved axillary lymph nodes per patient

(one to three vs four or more). Disease-free survival was the primary endpoint

and was defined as the interval between randomisation and breast cancer relapse,

second primary cancer, or death, whichever occurred first. Efficacy analyses were

based on the intention-to-treat principle. BCIRG 001 is registered with

ClinicalTrials.gov, number NCT00688740.

FINDINGS: Enrolement took place between June 11, 1997 and June 3, 1999; 745

patients were assigned to receive TAC and 746 patients were assigned to receive

FAC. After a median follow-up of 124 months (IQR 90-126), disease-free survival

was 62% (95% CI 58-65) for patients in the TAC group and 55% (51-59) for patients

in the FAC group (hazard ratio [HR] 0·80, 95% CI 0·68-0·93; log-rank p=0·0043).

10-year overall survival was 76% (95% CI 72-79) for patients in the TAC group and

69% (65-72) for patients in the FAC group (HR 0·74, 0·61-0·90; log-rank

p=0·0020). TAC improved disease-free survival relative to FAC irrespective of

nodal, hormone receptor, and HER2 status, although not all differences were

significant in these subgroup analyses. Grade 3-4 heart failure occurred in 26

(3%) patients in the TAC group and 17 (2%) patients in the FAC group, and caused

death in two patients in the TAC group and four patients in the FAC group. A

substantial decrease in left ventricular ejection fraction (defined as a relative

decrease from baseline of 20% or more) was seen in 58 (17%) patients who received

TAC and 41 (15%) patients who received FAC. Six patients who received TAC

developed leukaemia or myelodysplasia, as did three patients who received FAC.

INTERPRETATION: Our results provide evidence that the initial therapeutic

outcomes seen at the 5-year follow-up with a docetaxel-containing adjuvant

regimen are maintained at 10 years. However, a substantial percentage of patients

had a decrease in left ventricular ejection fraction, probably caused by

anthracycline therapy, which warrants further investigation.

FUNDING: Sanofi.

 

Copyright © 2013 Elsevier Ltd. All rights reserved.

 

PMID: 23246022  [PubMed - indexed for MEDLINE]

 

 

4. Ann Oncol. 2012 Oct;23 Suppl 7:vii92-9.

 

Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for

diagnosis, treatment and follow-up.

 

ESMO / European Sarcoma Network Working Group.

 

Collaborators: Blay JY, Blomqvist C, Bonvalot S, Boukovinas I, Casali PG, De

Alava E, Dei Tos AP, Dirksen U, Duffaud F, Eriksson M, Fedenko A, Ferrari A,

Ferrari S, del Muro XG, Gelderblom H, Grimer R, Gronchi A, Hall KS, Hassan B,

Hogendoorn P, Hohenberger P, Issels R, Joensuu H, Jost L, Jurgens H, Kager L, Le

Cesne A, Leyvraz S, Martin J, Merimsky O, Nishida T, Picci P, Reichardt P,

Rutkowski P, Schlemmer M, Sleijfer S, Stacchiotti S, Taminiau A, Wardelmann E.

 

PMID: 22997462  [PubMed - indexed for MEDLINE]

 

 

5. Oncologist. 2011;16(9):1197-202. doi: 10.1634/theoncologist.2011-0150. Epub 2011

Jun 28.

 

A prospective, controlled study of the botanical compound mixture LCS101 for

chemotherapy-induced hematological complications in breast cancer.

 

Yaal-Hahoshen N(1), Maimon Y, Siegelmann-Danieli N, Lev-Ari S, Ron IG, Sperber F,

Samuels N, Shoham J, Merimsky O.

 

Author information:

(1)Refuot Integrative Medical Center, 18 Feinstein Street, Tel Aviv 69123,

Israel.

 

Comment in

    Oncologist. 2012;17(5):740-1; author reply 742-3.

 

BACKGROUND: This prospective, controlled study evaluated the safety,

tolerability, and efficacy of the mixture of botanical compounds known as LCS101

in preventing chemotherapy-induced hematological toxicity in breast cancer

patients.

METHODS: Female patients diagnosed with localized breast cancer were randomly

allocated to receive treatment with either LCS101 or placebo capsules, in

addition to conventional chemotherapy. The study intervention was initiated 2

weeks prior to the initiation of chemotherapy and continued until chemotherapy

was completed, with participants receiving 2 g of LCS101 capsules thrice daily.

Subjects were assessed for the development of hematological and nonhematological

toxicities, as well as the tolerability and safety of the study intervention.

RESULTS: Sixty-five breast cancer patients were recruited, with 34 allocated to

LCS101 and 31 allocated to placebo treatment. Patients in the treatment group

developed significantly less severe (grades 2-4) anemia (p < .01) and leukopenia

(p < .03) when comparing grades 0-1 with grades 2-4, with significantly less

neutropenia (p < .04) when comparing grades 0-2 with grades 3-4. This effect was

more significant among patients undergoing a dose-dense regimen. No statistically

significant effect was found with respect to nonhematological toxicities, and

side effect rates were not significantly different between the groups, with no

severe or life-threatening events observed in either group.

CONCLUSION: The addition of LCS101 to anthracycline- and taxane-based

chemotherapy is safe and well tolerated, and may significantly prevent some

chemotherapy-induced hematological toxicities in early breast cancer patients.

These results should encourage further larger and more extensive clinical trials.

 

PMCID: PMC3228177

PMID: 21712486  [PubMed - indexed for MEDLINE]

 

 

6. Am J Clin Oncol. 2009 Feb;32(1):34-7. doi: 10.1097/COC.0b013e31817b6087.

 

The co-occurrence of breast cancer and soft tissue sarcoma in a single cohort

series.

 

Geva R(1), Jiveliouk I, Inbar M, Meller I, Friedman E, Merimsky O.

 

Author information:

(1)Unit of Bone and Soft Tissue Oncology, Division of Oncology, Tel-Aviv Sourasky

Medical Center, Tel-Aviv, Israel.

 

BACKGROUND: The incidence of breast cancer (BC) and soft tissue sarcoma (STS) in

the Israeli general population is 97/10 women and 1.5/10 persons. It is expected

that 1.5/10 x 49/10 of the women in the general population will have both BC and

STS.

METHODS: A retrospective search of 1350 adult STS patient files that were

recorded between 1995 and 2005.

RESULTS: One hundred thirty-four patients with STS had multiple primary

malignancies. BC was observed in 27/64 patients (42%) before/after the STS:

BC-first in 19/27, BC-later in 8/27. Of 19 with BC-first the STS was related to

radiotherapy in 2, and to lymphedema in 1. Of 8 STS-first, only 1 got

chemotherapy before BC. Median interval between first to second malignancies was

6.9 years for BC-first, and 3.8 for BC-later. The incidence of BC among all

patients with STS-first followed by a second malignancy is 8/58 (14%), or 27/890

(3%) of all women STS-patients in the registry. The incidence of STS among the BC

patients was low, and most of our cases were therapy unrelated. Median survival

for BC-first was 305 months, versus 213 for STS-first.

CONCLUSIONS: BC and STS may naturally occur in the same individual. The etiology

for this phenomenon is unclear. Practically, BC screening in patients with STS is

warranted.

 

PMID: 19194122  [PubMed - indexed for MEDLINE]

 

 

7. Oncology. 2009;76(1):30-5. doi: 10.1159/000178162. Epub 2008 Nov 26.

 

Ductal carcinoma in situ of the breast in Israeli women treated by

breast-conserving surgery followed by radiation therapy.

 

Jiveliouk I(1), Corn B, Inbar M, Merimsky O.

 

Author information:

(1)Department of Oncology, Tel-Aviv Sourasky Medical Center, affiliated with the

Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.

 

BACKGROUND: Lumpectomy followed by radiation therapy (RT) has become an accepted

local management strategy for patients with small, mammographically detected

ductal carcinoma in situ (DCIS) of the breast. The aim of this analysis is to

describe control rates and patterns of relapse in a cohort of Israeli women with

mammographically detected DCIS treated at a single medical center.

PATIENTS AND METHODS: The files of 107 consecutive patients with DCIS were

retrieved from the cancer registry of the unit of RT. All women underwent

lumpectomy followed by definitive RT, administered in conventional dose

fractionation regimens. Oral tamoxifen, 20 mg/ day, was prescribed to all but 2

patients with positive receptors.

RESULTS: Within a median follow-up time of 52 months, no local recurrence of any

breast tumor was found. There was no correlation between event-free survival and

tumor size, focality, grading, hormone receptor status, administration of

adjuvant hormonal therapy, timing of RT, and RT boost delivery. The 8-year

overall survival, disease-free-survival, and event-free survival were 100, 100,

and 87%, respectively.

CONCLUSIONS: The results reported herein are consistent with short-term and

intermediate-term outcomes that are better than the reported benchmarks from

prospective randomized trials. Although this could reflect selection factors at a

single institution, it is also plausible that a genetically distinct disease is

present in this local population.

 

PMID: 19033713  [PubMed - indexed for MEDLINE]

 

 

8. Anticancer Res. 2008 Sep-Oct;28(5B):3147-52.

 

Invasive breast cancer treated with taxol and epirubicin neo-adjuvant

chemotherapy: the role in the outcome of the "crosstalk" between Erb receptors

and p53.

 

Sarid D(1), Ron IG, Shoshan L, Barnea I, Shina S, Baratz M, Greenberg J, Merimsky

O, Ben-Yosef R, Lev-Ari S, Keidar Y, Yaal-Hahoshen N.

 

Author information:

(1)Department of Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.

 

PURPOSE: To correlate p53 and ErbB receptors status with disease-free survival

(DFS) and overall survival (OS) in locally advanced breast cancer.

PATIENTS AND METHODS: Sixty patients were included in a single-center,

open-label, phase II trial (1998-2003). Analysis of Erb receptors and p53 status

and estrogen receptor/progesterone receptor data were available for 33 patients.

Neoadjuvant epirubicin 75 mg/m2 and paclitaxel 175-200 mg/m2 were administered

every 21 days. The patients underwent surgery and radiation therapy and adjuvant

chemo/hormonotherapy.

RESULTS: Approximately two thirds of the patients demonstrated overexpression of

ErbB receptors and had mutant p53 overexpression. The disease recurred in 11/33

patients and 7 died (median follow-up 56 months). Detrimental effects on OS were

established in cases of combined defective p53 expression and ErbB1-ErbB3

heterodimeric receptor overexpression. In contrast, normal p53 together with the

same overexpressed heterodimeric combination of ErbB receptors showed no

statistically significant effect.

CONCLUSION: In terms of the clinical impact of combinations of ErbB receptors

with or without mutant p53, only the overexpressed various ErbB1-ErbB3 dimeric

combinations and the ErbB1/ErbB2/ErbB3 triplet combination with mutated p53 were

related to a significantly poorer outcome. This observation may help in the

development of new strategies required for blocking these molecular pathways and

improving the outcome of patients with locally advanced breast cancer.

 

PMID: 19031973  [PubMed - indexed for MEDLINE]

 

 

9. Br J Ophthalmol. 2007 Jan;91(1):74-5. Epub 2006 Aug 30.

 

Decreased prevalence of asymptomatic choroidal metastasis in disseminated breast

and lung cancer: argument against screening.

 

Barak A(1), Neudorfer M, Heilweil G, Merimsky O, Lowenstein A, Inbar M,

Yaal-Hahoshen N.

 

Author information:

(1)Department of Ophthalmology, Tel Aviv Sourasky Medical Center, Sackler Faculty

of Medicine, Tel Aviv University, 6 Weizman Street, Tel Aviv 64239, Israel.

adielbarak@gmail.com

 

AIM: To determine the frequency of visually asymptomatic choroidal metastases in

patients with disseminated breast and lung carcinomas in order to establish

optimal patient management policies.

METHODS: All patients with confirmed metastatic disease treated in our

institution between January 2002 and December 2003 were invited to undergo a

funduscopic examination and a B-scan ultrasound evaluation.

RESULTS: Of the 169 study participants, 77 had breast cancer (64 with metastases

in one organ and 13 with multiple-organ involvement) and 92 had lung cancer (85

with metastases in one organ and 7 with multiple-organ involvement). No patient

with metastatic breast cancer and two patients with metastatic lung disease (each

with multiple-organ involvement) were found to have choroidal metastases. The

choroidal metastases were detected by both the funduscopic and ultrasound

examinations.

CONCLUSIONS: The 2.17% incidence of choroidal metastasis in disseminated lung

cancer and the 0% incidence in disseminated breast cancer speaks against the

practicality of screening for early detection of choroidal metastasis among these

patients, even though it would lead to early implementation of appropriate, often

vision saving, therapeutic management. Its low incidence probably testifies to

progress achieved by enhanced systemic oncological treatment policies that have

been introduced into routine patient management over the past few years.

 

PMCID: PMC1857549

PMID: 16943227  [PubMed - indexed for MEDLINE]

 

 

10. Isr Med Assoc J. 2000 Oct;2(10):786.

 

Herceptin-taxol related hand and foot syndrome.

 

Merimsky O(1), Inbar MJ.

 

Author information:

(1)Department of Oncology, Tel Aviv Sourasky Medical Center and Sackler Faculty

of Medicine, Tel Aviv University, Israel. merimsky@zahav.net.il

 

PMID: 11344738  [PubMed - indexed for MEDLINE]

 

 

11. Cancer. 2001 Apr 1;91(7):1363-71.

 

Multiple primary malignancies in association with soft tissue sarcomas.

 

Merimsky O(1), Kollender Y, Issakov J, Bickels J, Flusser G, Gutman M,

Lev-Chelouche D, Inbar M, Meller I.

 

Author information:

(1)Department of Oncology, The Tel-Aviv Sourasky Medical Center, the Sackler

School of Medicine, Tel-Aviv University, Tel-Aviv, Israel. merimsky@zahav.net.il

 

BACKGROUND: Modern cancer treatment has increased the survival of patients with

various malignancies substantially. One of the late sequelae of successful

treatment is the development of a second malignant tumor. However, in many cases

of second primary tumors, exposure to chemotherapy or radiation therapy is not

evident, and it should be postulated that the putative mechanism for the

development of the second tumor is different. In the current series, the

association between soft tissue sarcoma (STS) in adults and the development of

other primary malignancies was studied.

METHODS: A retrospective search of the data files of 610 patients with STS or

bone sarcomas who were treated at the study institution between January 1995 and

December 1999 was performed. All files regarding patients with STS who developed

a second malignant tumor were retrieved for analysis.

RESULTS: Of 375 patients with STS, 28 (7.5%) developed other malignant neoplasms

either before or after the diagnosis of STS. STS as the first tumor occurred in

14 patients (ages 16-72 years). Only three patients were treated with

chemotherapy for their sarcoma. Radiation therapy was administered to five

patients as an adjuvant to surgery for the first tumor. The second tumor types

mainly included STS and renal cell carcinoma. The time interval between the

diagnosis of the STS and the second malignancy was 0 (for synchronous tumors) to

21 years. Three patients developed a third primary tumor within 3 years after the

diagnosis of the second tumor. The median overall survival was > 78 months.

Fourteen patients (ages 35-87 years) had a first primary tumor other than STS

(mainly breast carcinoma and genitourinary malignancies). The second tumors

(mainly STS) appeared within 0 (for synchronous tumors) to 27 years. The median

overall survival for the 14 patients in this group from the time of diagnosis of

the first tumor was > 102 months.

CONCLUSIONS: The phenomenon of two or three primary neoplasms developing in

patients in whom one of the tumors was STS occurs at a rate of 7.5%, a

significantly higher rate than that reported for the occurrence of STS among the

general cancer population (1%). The majority of cases occur incidentally. The

clinical implication includes the need to search for an occult second primary

tumor in patients with STS as an integral part of their follow-up. This is

especially true in patients with primary malignant fibrous histiocytoma who

demonstrate a risk for developing a renal cell carcinoma.

 

Copyright 2001 American Cancer Society.

 

PMID: 11283938  [PubMed - indexed for MEDLINE]

 

 

12. Eur J Surg Oncol. 1999 Oct;25(5):483-6.

 

Clips and scar as the guidelines for breast radiation boost after lumpectomy.

 

Kovner F(1), Agay R, Merimsky O, Stadler J, Klausner J, Inbar M.

 

Author information:

(1)Tel-Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel-Aviv

University, Israel. kfelix@iol.co.il

 

BACKGROUND AND AIMS: Breast-conserving therapy in early breast cancer is equally

effective as mastectomy, with advantages of cosmesis and quality of life over

mastectomy. Local control is improved when entire breast irradiation is combined

with a radiation boost to the tumour bed.

METHODS: Localization of the tumour bed was compared in 45 consecutive patients

using surgical scar and radiopaque clips placed intra-operatively in the

lumpectomy cavity.

RESULTS: The area (A) of the radiation boost field and volume (V) of the tumour

bed, designed on the basis of scar (AS and VS), were 1.4 times larger than those

designed on the basis of the clips (AC and VC). AS and VS missed about

one-quarter of the tumour bed which had been delineated by clips

intra-operatively, while about one-half of it encompassed tissues beyond the AC

and VC.

CONCLUSIONS: A boost planned by scar dimensions can miss a substantial portion of

the tumour bed, compromising local control. On the other hand, a substantial

amount of breast tissue beyond the tumour bed can be unnecessarily irradiated,

compromising cosmetic treatment results. Thus, the scar provides an inadequate

landmark for radiation boost planning in breast-conserving therapy.

 

PMID: 10527596  [PubMed - indexed for MEDLINE]

 

 

13. J Neurooncol. 1999 Mar;42(1):85-92.

 

Radiation therapy of metastatic spinal cord compression. Multidisciplinary team

diagnosis and treatment.

 

Kovner F(1), Spigel S, Rider I, Otremsky I, Ron I, Shohat E, Rabey JM, Avram J,

Merimsky O, Wigler N, Chaitchik S, Inbar M.

 

Author information:

(1)Department of Oncology, Tel-Aviv Sourasky Medical Center, Sackler Faculty of

Medicine, Tel-Aviv University, Israel. kfelix@iol.co.il

 

PURPOSE: To evaluate the effectiveness of a multidisciplinary approach to spinal

cord compression (SCC) in accordance with prospective protocol, providing a

uniform approach to diagnosis, decision making concerning optimal treatment

modality in any particular case of SCC, treatment performance and evaluation of

treatment results. The SCC patients treated by radiation therapy are described.

MATERIALS AND METHODS: Patients with SCC were examined and treated by a

multidisciplinary team consisting of a neurologist, radiologist, oncologist,

orthopedic surgeon, and neurosurgeon. Seventy-nine patients for whom radiation

was recommended received a 30 Gy radiation dose to a compression-causing mass and

course of high dose dexamethasone. Three fractions of 5 Gy and 5 fractions 3 Gy

each were delivered by Co60 or 8 MV photon beam in 12 days. Treatment outcome was

essentially evaluated by ambulation capabilities which were considered to be the

main problem of SCC. Changes in other neurologic motor, sensory and autonomic

disturbances were also evaluated.

RESULTS: Seventy-two percent of the patients were already non-ambulatory at

diagnosis. The first symptom was motor deficiency in only 33% of them while in

all other cases it was pain. Ambulation capability was the main prognosticator of

treatment outcome; 90% of patients who were ambulatory before treatment remained

so while 33% of the non-ambulatory patients regained their ability to walk. The

grade of motor disturbance was also an important variable: among the

non-ambulatory patients, 50% of the paretic but only 14% of the plegic ones

became ambulatory. Overall, 51% of the study patients were ambulatory after

undergoing radiation. The ambulatory state after treatment was the main predictor

for survival.

CONCLUSION: Close cooperation of a multidisciplinary team in diagnosis and

treatment according to the above protocol enabled the achievement of good results

of radiation treatment in SCC. Early diagnosis and early treatment should further

enhance therapeutic outcome.

 

PMID: 10360483  [PubMed - indexed for MEDLINE]

 

 

14. J Neurooncol. 1998 Jan;36(1):79-83.

 

Primary intramedullary spinal melanoma: diagnostic and treatment problems.

 

Salame K(1), Merimsky O, Yosipov J, Reider-Groswasser I, Chaitchik S, Ouaknine

GE.

 

Author information:

(1)Department of Neurosurgery, Tel-Aviv Sourasky Medical Center and Sackler

School of Medicine, Israel.

 

A 76-year old female patient with 9 year history of right mastectomy for an

infiltrating ductal breast cancer and no evidence of recurrent nor metastatic

disease, was admitted due to pain in the lower thoracic area radiating

bilaterally to the posterior aspect of the chest wall at the same level,

difficulties in micturition, urinary hesitancy, and progressive weakness of the

lower limbs. Primary intramedullary spinal tumor was demonstrated by a MRI study

of the spine, partially resected, and found to be a malignant melanoma on

pathological study. Postoperative irradiation and administration of dexamethasone

did not improve the neurologic status.

 

PMID: 9525829  [PubMed - indexed for MEDLINE]

 

 

15. Oncol Rep. 1997 Jul-Aug;4(4):843-7.

 

Tamoxifen for disease-negative but MCA-positive breast cancer patients.

 

Merimsky O, Kovner F, Inbar M, Hareuveni M, Rosenboim Y, Chaitchik S.

 

Increased levels of mucin-like carcinoma-associated antigen (MCA) in breast

cancer patients with no evidence of disease following the treatment of the

primary disease created a dilemma of 'to treat' or 'wait and see'. One might

assume that early treatment of clinically undetectable disease on the basis of an

elevated serum level of a sensitive and reliable tumor marker, may improve the

treatment results, and even prolong the patient's survival. 'Wait and see' on

acceptance of the notion that even early metastatic disease, still manifested

only by uprising MCA levels, is incurable, and treatment should be kept in

reserve for palliation of symptomatic disease. Sixty-one breast cancer patients

with increasing MCA levels but without evidence of metastatic disease were

randomized for tamoxifen 20 mg b.i.d. or to follow-up till relapse. The results

for a median follow-up period of one year were encouraging. The non-treated

patients experienced a significantly higher relapse rate (24.1%) than the

tamoxifen-treated subjects (0%; p=0.012). The results for a median follow-up of 5

years were disappointing. The overall relapse rate was 22.2%. The relapse rate

among the control patients was 25.8% while in the treatment arm it was 17.4%

(p=0.46). The event-free survival and the pattern of relapse were similar in both

arms. Tamoxifen may therefore be reserved for overt metastases, and not wasted on

asymptomatic subclinical disease. It seems that there is no yield in terms of

event-free survival for MCA measurements in breast cancer patients during the

5-year follow-up period.

 

PMID: 21590154  [PubMed]

 

 

16. Oncol Rep. 1997 Jul-Aug;4(4):829-32.

 

Elevated breast cancer serum markers in otherwise healthy women.

 

Merimsky O(1), Hareuveni M, Barak V, Sperber F, Eshkol Z, Chaitchik S.

 

Author information:

(1)TEL AVIV UNIV,SACKLER FAC MED,TEL AVIV SOURASSKY MED CTR,DEPT ONCOL,IL-69978

TEL AVIV,ISRAEL. TEL AVIV UNIV,SACKLER FAC MED,TEL AVIV SOURASSKY MED CTR,DEPT

RADIOL,IL-69978 TEL AVIV,ISRAEL. HADASSAH MED CTR,TUMOR MARKER RES UNIT,IL-91120

JERUSALEM,ISRAEL. HEBREW UNIV JERUSALEM,JERUSALEM,ISRAEL.

 

A high value of mucin-like carcinoma associated antigen (MCA), CA-15.3 or H23, in

a woman known to have a diagnosis of breast cancer, may reflect presence of

disease. A low level in a breast cancer patient may be accepted for remission,

but a false negative result cannot be excluded. On the other hand, a low level of

serum tumor marker in the general population actually lacks any significance.

However, what is the meaning of an elevated level of marker, known to have a

relatively high sensitivity and specificity, in an otherwise healthy woman? Does

it mean an occult breast cancer or a false positive? Sera samples were obtained

from 155 consecutive, otherwise healthy women, who were referred for mammography,

and assayed for tumor markers. MCA was elevated in 15-24% of patients with normal

mammogram, depending on their ages. Lack of elevation of a second marker in most

of the cases supported the assumption that the elevation of the MCA was

insignificant. Elevation of H23 occurred more frequently in younger women than in

the elders, but was not associated with elevation of a second marker. In the

cases with abnormal mammogram due to histologically proven benign disorders,

serum tumor markers were generally within the normal ranges. Our results pointed

to the lack of diagnostic significance of an elevated level of serum tumor

marker, as far as the mammogram was normal or benign, there was no history of

cancer nor any other systemic disease (including malignancy), and a second tumor

marker was within the normal range. The women with presently false positive

marker level may, however, be followed, because of the possible risk for future

development of breast cancer.

 

PMID: 21590151  [PubMed]

 

 

17. Oncol Rep. 1996 Jan;3(1):197-9.

 

Fluorescence polarization changes in the lymphocytic cytoplasm in the various

stages of breast cancer.

 

Ron I(1), Deutsch M, Merimsky O, Tirosh R, Rachmani H, Kaufman M, Weinreb A,

Chaitchik S.

 

Author information:

(1)TEL AVIV UNIV,TEL AVIV SOURASKY MED CTR,DEPT ONCOL,IL-69978 TEL AVIV,ISRAEL.

TEL AVIV UNIV,SACKLER FAC MED,IL-69978 TEL AVIV,ISRAEL. BAR ILAN UNIV,DEPT

PHYS,JEROME SCHOTTENSTEIN CELLSCAN CTR EARLY DETECT CA,RAMAT GAN,ISRAEL. TEL AVIV

UNIV,BEILINSON HOSP,DEPT SURG B,IL-69978 TEL AVIV,ISRAEL.

 

Post-surgical pathological staging and ancillary tests determine the initial

treatment of breast cancer. Because change in the structuredness of the

cytoplasmic matrix (SCM) of peripheral lymphocytes (as assessed by measurement of

fluorescein fluorescence polarization, FFP) has already emerged as diagnostic for

breast cancer and an aid to staging in other cancers, testing was carried out in

113 pre-surgical patients to see whether such change could contribute to accurate

staging of breast cancer. The FFP test was able to distinguish grouped stages of

locoregional disease from metastatic disease but was unable to distinguish

between any single locoregional stage and the metastatic stage. Technological

improvements now underway may create a role for assessment of SCM changes in

breast cancer staging.

 

PMID: 21594343  [PubMed]

 

 

18. Eur J Cancer. 1996 Jan;32A(1):174.

 

Adjuvant tamoxifen: 5 year control of dormant disease?

 

Merimsky O, Inbar M, Kovner F, Chaitchik S.

 

PMID: 8695228  [PubMed - indexed for MEDLINE]

 

 

19. Oncol Rep. 1995 Sep;2(5):781-5.

 

Breast-cancer associated brachial plexopathy - still a diagnostic and treatment

challenge.

 

Merimsky O(1), Rabey J, Inbar M, Chaitchik S.

 

Author information:

(1)ICHILOV HOSP,TEL AVIV SOURASKY MED CTR,DEPT NEUROL,IL-64239 TEL AVIV,ISRAEL.

TEL AVIV UNIV,SACKLER FAC MED,IL-69978 TEL AVIV,ISRAEL.

 

Brachial plexopathy (BP) in breast cancer patients is a rare event, attributed

mainly to radiation damage or tumor infiltration of the plexus. Differentiation

between these etiologies is a diagnostic challenge. We have studied

retrospectively eight female patients with breast cancer who developed a clinical

syndrome of brachial plexopathy following the treatment of the primary disease,

out of more than 900 during the last 10 years. None of the available ancillary

tests such as plain films, CT or MRI studies, EMG or tumor markers, provided

reliable data regarding the cause of the plexopathy. Biopsy, on the other hand,

was not always feasible. In our series, all the patients who developed BP did not

have any blood-borne metastases before developing the syndrome. In 3 of the

patients BP was the first sign of recurrence. In the other 5, only local or

locoregional relapse preceded. In 7 of the 8 patients the left side was affected.

Treatment should be tailored in each case according to course of the disease. The

optimal treatment has not yet been defined.

 

PMID: 21597816  [PubMed]

 

 

20. Anticancer Drugs. 1994 Dec;5(6):666-9.

 

Chemotherapy-related persistent indirect hyperbilirubinemia.

 

Inbar M(1), Merimsky O, Chaitchik S.

 

Author information:

(1)Department of Oncology, Tel-Aviv Sourasky Medical Center, Israel.

 

In spite of the improvement on chemotherapy results in treating testicular cancer

and the introduction of adjuvant chemotherapy to node negative (as well as node

positive) breast cancer patients, there is still present a wide spectrum of early

and late toxic manifestations. The combination of cisplatin, vinblastine and

bleomycin given to testicular cancer might result in cariovascular, neurological,

gastrointestinal and renal problems. Late effects of cyclophosphamide,

methotrexate and 5-fluorouracil given to breast cancer patients might cause

obesity, amenorrhea and infertility. We report a persistent asymptomatic indirect

hyperbilirubinemia which was observed in two cancer patients (breast; testis) 3

and 14 months following the cessation of chemotherapy. Metastatic liver disease

and involvement of other sites, as well as other causes of hyperbilirubinemia,

were excluded. The exact cause of the indirect hyperbilirubinemia remained

obscure.

 

PMID: 7888704  [PubMed - indexed for MEDLINE]

 

 

21. Int J Radiat Oncol Biol Phys. 1994 Nov 15;30(4):831-7.

 

Postoperative high dose-rate intravaginal brachytherapy combined with external

irradiation for early stage endometrial cancer: a long-term follow-up.

 

Nori D(1), Merimsky O, Batata M, Caputo T.

 

Author information:

(1)Department of Radiation Oncology, New York Hospital Medical Center of Queens,

Flushing 11355.

 

PURPOSE: To evaluate the long-term control of disease and cure rate,

complications, second malignancy, and survival of early-stage endometrial cancer

patients treated with surgery, high dose-rate brachytherapy, and external beam

radiation therapy.

METHODS AND MATERIALS: From 1969 through 1979, 300 patients with clinically

staged Stage I-II endometrial cancer underwent total abdominal hysterectomy and

bilateral salpingo-oopherectomy, followed by high dose-rate intravaginal

radiation, 7 Gy x 3 to 0.5 cm from the mucosal surface, using a remote

afterloading technique. External beam radiation therapy, 40 Gy to midplane in 4

weeks, was delivered to high risk patients through AP/PA and lateral fields.

RESULTS: The patients were followed for 5-24 years (median 12). The actuarial

progression-free survival rate was 96.6%. Post-treatment grade 1-2 actuarial

complication rate was 9.5%, including cystitis (4.5%), vaginal stenosis (2.5%),

proctitis (1.5%), vaginal necrosis (0.5%), and partial bowel obstruction (0.5%).

Neither grade 3-4 complications nor additional late complications were observed

in any of our patients. Relapse rate was only 3.7%, of which 45.5% were local,

45.5% were distant, and 9% were mixed. All the patients with relapse were

postmenopausal, age range of 58-77 years, with tumor grade 2-3 in 64%. Second

primary cancer rate was 12.8% (mostly breast and colon). Factors that were

associated with improved prognosis were young age, premenopausal, low grade, no

extrauterine disease, and a histology of adenocarcinoma (adenocarcinoma with

squamous metaplasia).

CONCLUSION: High dose rate intravaginal radiation therapy combined with surgery

and external beam radiation therapy achieved a high cure rate small number of

minor complications. No long-term treatment-related complications were noted in

any of the patients. This treatment combination may be safely applied to patients

with early stage endometrial cancer.

 

PMID: 7960984  [PubMed - indexed for MEDLINE]

 

 

22. Cancer Chemother Pharmacol. 1994;35(1):80-3.

 

Treatment of disease-negative but mucin-like carcinoma-associated

antigen-positive breast cancer patients with tamoxifen: preliminary results of a

prospective controlled randomized trial.

 

Kovner F(1), Merimsky O, Hareuveni M, Wigler N, Chaitchik S.

 

Author information:

(1)Department of Oncology, Tel-Aviv Sourasky Medical Center, Israel.

 

Increasing levels of tumor markers such as carcinoembryonic antigen, mucin-like

carcinoma-associated antigen (MCA), CA 15.3, and monoclonal antibody H23 in

breast cancer patients following the treatment of the primary disease and

adjuvant radiation and chemotherapy reflect subclinical development of metastatic

disease. Overt metastatic disease is usually incurable and prolongation of life

at this stage is impossible, and the treatment is only palliative. The efficacy

of tamoxifen, a least-toxic agent, in the treatment of early and minimal

metastatic disease detected only by increasing serum levels of MCA was studied

prospectively in a randomized study. Our preliminary, albeit encouraging, results

showed that the rate of relapse within a median follow-up period of 11 months was

24.1% in the control arm as compared with 0% in the tamoxifen arm (Fisher's exact

test, P = 0.012). None of the patients with a relapse had positive progesterone

receptors (PR). We may carefully conclude that early treatment may be warranted

in young patients with negative PR and continuously increasing serum levels of

the marker.

 

PMID: 7987981  [PubMed - indexed for MEDLINE]

 

 

23. Tumori. 1992 Dec 31;78(6):407-8.

 

Kaposi's sarcoma on a lymphedematous arm following radical mastectomy.

 

Merimsky O(1), Chaitchik S.

 

Author information:

(1)Department of Oncology, Tel-Aviv Sourasky Medical Center, Israel.

 

Chronic lymphedema predisposes for local immune incompetence, manifested by

development of Stuart-Treves syndrome, Kaposi's sarcoma and fibroma-like lesions.

A 91-year-old female with multiple cancers developed classic Kaposi's sarcoma on

a chronically lymphedematous arm 26 years after radical mastectomy and

irradiation of the involved axilla. The Kaposi lesion partially responded to

electron beam irradiation.

 

PMID: 1297238  [PubMed - indexed for MEDLINE]

 

 

24. Eur J Cancer. 1991;27(11):1440-4.

 

Serial serum MCA measurements in the follow-up of breast cancer patients.

 

Merimsky O(1), Inbar M, Hareuveni M, Witenberg B, Wolman Y, Chaitchik S.

 

Author information:

(1)Department of Oncology, Tel-Aviv Sourasky Medical Center, Sackler Faculty of

Medicine, Tel-Aviv University, Israel.

 

Mucin-like carcinoma-associated antigen (MCA) was serially assayed in 58 women

with histologically proven breast cancer after their treatment for primary

disease. MCA sensitivity and specificity were 87.5% and 76.9%, respectively, and

the positive predictive value 82.4%. 10 patients had elevated MCA and no evidence

of disease (NED) during their follow-up, of whom 4 finally developed overt

metastases. The 4 had a mean (S.D.) MCA value of 46.48 (18.26) U/ml during the

lead time, versus 18.76 (2.69) U/ml in the other 6, who are still at high risk

for developing overt metastases. Raised levels of MCA in patients with NED create

a dilemma of "treat" versus "wait and see". Early treatment of patients with

serially uprising MCA levels should be evaluated in a prospective randomised

study to assess its ability to prevent or delay the development of overt

metastatic disease and influence survival.

 

PMID: 1835861  [PubMed - indexed for MEDLINE]

 

 

25. Tumori. 1990 Dec 31;76(6):548-51.

 

Metastatic disease of the cavernous sinus: contribution of computed tomography

and magnetic resonance imaging to diagnosis.

 

Merimsky O(1), Reider I, Inbar M, Kovner F, Chaitchik S.

 

Author information:

(1)Department of Oncology, Tel-Aviv Sourasky Medical Center, Israel.

 

The clinical presentation of metastatic disease to the cavernous sinus includes

ophthalmoplegia, pain and sensory deficit along the optic or maxillary branches

of the trigeminal nerve. The role of a CT scan and magnetic resonance imaging in

the diagnosis is discussed. It was found that magnetic resonance imaging is

superior to CT scan in demonstrating the cavernous sinus and pontine borders,

especially in lymphomatous involvement of these structures.

 

PMID: 2284690  [PubMed - indexed for MEDLINE]

 

 

26. Tumori. 1990 Aug 31;76(4):407-9.

 

Recurrent solitary metastasis of renal cell carcinoma in skeletal muscles.

 

Merimsky O(1), Levine T, Chaitchik S.

 

Author information:

(1)Department of Oncology, Ichilov Hospital Tel-Aviv Medical Center, Israel.

 

Metastatic carcinoma to skeletal muscle is uncommon and may originate from

breast, colon, lung, pancreas and other sources. Recurrent solitary metastases of

renal cell carcinoma in the biceps femori and gluteus muscles are described in a

69 year-old man. The tendency of metastases to occur merely in muscles could not

be explained in our case. The relative immunity of muscle to the metastatic

process should be further investigated.

 

PMID: 2399572  [PubMed - indexed for MEDLINE]